Nektar Therapeutics has been downgraded from Strong Buy to Hold due to safety concerns related to its drug REZPEG, despite positive efficacy results from the Phase 2b REZOLVE-AA study. The study showed 63% durability off-treatment but revealed a high rate of injection site reactions at 91.7%, raising doubts about REZPEG's commercial potential in treating alopecia areata (AA). The company maintains a strong cash position of $1.02 billion as of June 2026, which supports operations until Q3 2028 and reduces near-term dilution risk. While Phase 3 programs for ZENITH AD and AA are progressing, the high incidence of side effects and uncertain regulatory outcomes temper the investment outlook for Nektar.
Nektar Therapeutics shares provide context for this health sector snapshot. For readers following health stocks, here is Pluang's market snapshot as of Oct 03, 2026 03:21 WIB: Out of 100 priced health-sector US stocks, 32 rose and 67 fell. Alnylam Pharmaceuticals (ALNY) traded at USD 219.92 with a 1-day change of -4.87%, AbCellera Biologics (ABCL) at USD 13.89 down 4.80%, and Danaher Corporation (DHR) at USD 211.68 down 4.47%. Typical hold times ranged from 40 to 69 days, with strong buy order activity for ALNY and DHR but heavy sell pressure on ABCL.
NextEra Energy and partners are developing Project Star, a $22.3 billion natural gas-powered energy campus in Encinal, Texas, aimed at powering a large data center and supplying the grid. The campus will have 6.47 gigawatts of generation capacity, wi...
UBS has increased its price target for G-III Apparel Group to $27.00 from $26.00, reflecting confidence in the company's financial health and market position. Although the current share price slightly exceeds UBS's target, other analysts see potentia...
Enerflex secured a contract to build about 450 megawatts of natural gas-fired power units for a North American data center developer, with deliveries starting in 2027 and completing in 2028. The company’s 2026 capital spending includes $15 million fo...
UBS lowered its price target for McCormick from $52 to $48 following the company's Q3 fiscal 2026 results. Although McCormick beat expectations and confirmed its full-year outlook, its net income fell sharply to $97.6 million from $225.5 million year...
Allison Transmission Holdings completed a partial redemption of $100 million of its 4.75% senior notes due in 2027 on September 30, 2026. The notes were redeemed at full principal value plus accrued interest. After this redemption, $300 million of th...
